Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition

Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2018
Teme:
Brief Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://ncbi.nlm.nih.gov/pubmed/29942923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki